Encaleret - BridgeBio Pharma
Alternative Names: BBP-305; CLTX-305; Encaleret SulfateLatest Information Update: 05 Mar 2026
At a glance
- Originator Calcilytix therapeutix
- Developer BridgeBio Pharma; Calcilytix Therapeutics
- Class Amines; Benzoic acids; Calcium regulators; Ethers; Halogenated hydrocarbons; Osteoporosis therapies; Small molecules
- Mechanism of Action Calcium-sensing receptor antagonists; Parathyroid hormone receptor agonists
-
Orphan Drug Status
Yes - Hypocalcaemia; Hypoparathyroidism
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Hypocalcaemia; Hypoparathyroidism
Most Recent Events
- 25 Feb 2026 BridgeBio announced intention to launch encalret in late 2026/early 2027
- 14 Jan 2026 Phase-II/III clinical trials in Hypocalcaemia (In children, In infants, In neonates, In adolescents, Treatment-experienced) in USA (PO) (NCT07080385)
- 12 Jan 2026 BridgeBio completes End-of-phase II meeting with the US FDA